Related references
Note: Only part of the references are listed.Results of Phase 2 Randomized Study of Low-Dose Decitabine With or Without Valproic Acid in Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia
Jean-Pierre Issa et al.
CANCER (2015)
Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome
Barbara Deschler et al.
HAEMATOLOGICA (2013)
Epigenetic Priming of AML Blasts for All-trans Retinoic Acid-Induced Differentiation by the HDAC Class-I Selective Inhibitor Entinostat
Nadja Blagitko-Dorfs et al.
PLOS ONE (2013)
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
Michael Luebbert et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
Andres O. Soriano et al.
BLOOD (2007)
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
William Blum et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
Guillermo Garcia-Manero et al.
BLOOD (2006)
Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia
Giuseppe Cimino et al.
CANCER RESEARCH (2006)
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial
Donald W. Milligan et al.
BLOOD (2006)
Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents
H Araki et al.
EXPERIMENTAL HEMATOLOGY (2006)
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia
G Bug et al.
CANCER (2005)
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia
A Kuendgen et al.
ANNALS OF HEMATOLOGY (2005)
The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells
MR Trus et al.
LEUKEMIA (2005)
Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells
G Bug et al.
CANCER RESEARCH (2005)
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia
RF Schlenk et al.
LEUKEMIA (2004)
Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A
M Milhem et al.
BLOOD (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
